EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome

Gema Ariceta iD

Expert Review of Clinical Pharmacology · 2023

DOI: 10.1080/17512433.2023.2209317 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, 2023. Verfasst von Gema Ariceta. Beteiligte Einrichtung: Pediatric Nephrology, Hospital Universitari Vall d'Hebron. Universitat Autonoma Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal, Atypical Hemolytic Uremic Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 102 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) are two rare and severe conditions caused by chronic complement (C') system dysregulation. Treatment with eculizumab, a recombinant, humanized monoclonal antibody against complement C5, changed the natural history of both diseases inducing remission and improving patient outcome. Ravulizumab, a new long-acting next-generation C5 inhibitor, has been recently approved for treatment of PNH and aHUS. AREAS COVERED: Main characteristics of ravulizumab are described: composition, dosing, efficacy and safety profile. Further, an overview of seminal studies and clinical trials using ravulizumab to treat PNH and aHUS in children and adults is detailed. Literature review was performed using the following key words: paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and ravulizumab. EXPERT OPINION: Ravulizumab profile to treat PNH and aHUS is equivalent to eculizumab in efficacy and safety but allows extended dosing interval to every 4-8 weeks based on patient weight, and requires reduced infusion time. Less travels to infusion centers and medical visits and decreasing job and school absences significantly increase patient and families' QoL, while reducing cost. Further infusion time is reduced. Ravulizumab will possibly become the treatment of choice for patients with PNH and aHUS on chronic C5 inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemoglobinuria, ParoxysmalAtypical Hemolytic Uremic SyndromeAdultChildHumansComplement Inactivating AgentsQuality of LifeComplement C5Antibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Complementatypical hemolytic uremic syndromeeculizumabparoxysmal nocturnal hemoglobinuriaquality-of-liferavulizumab

Substanzen

Complement Inactivating AgentsComplement C5ravulizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Pediatric Nephrology, Hospital Universitari Vall d'Hebron. Universitat Autonoma Barcelona, Barcelona, Spain.

ORCID-Profile: Gema Ariceta

Zitieren

APA

Ariceta, G. (2023). Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2023.2209317

Vancouver

Ariceta G. Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Expert Review of Clinical Pharmacology. 2023. doi:10.1080/17512433.2023.2209317

BibTeX
@article{Ariceta2023,
  author = {Ariceta, Gema},
  title = {Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2023},
  doi = {10.1080/17512433.2023.2209317}
}
Kostenlos starten →